Patents by Inventor Tien WIDJAJA

Tien WIDJAJA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPIOID RECEPTOR MODULATORS
    Publication number: 20240092746
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: February 13, 2023
    Publication date: March 21, 2024
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI
  • Fluoroalkyl-oxadiazoles and uses thereof
    Patent number: 11926622
    Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: March 12, 2024
    Assignee: Tenaya Therapeutics, Inc.
    Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20240051948
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 15, 2024
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11878970
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: January 23, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Xiaohong Chen, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Johnathan Alexander McLean, Gerit Maria Pototschnig, Hua-Yu Wang, Michael Brian Welch, Tien Widjaja
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11873295
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: January 16, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Alfredo Picado, Gerit Maria Pototschnig, Michael Brian Welch, Tien Widjaja, Xiaohong Chen, Nathan Edward Wright, Hua-Yu Wang
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230286960
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11649227
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 16, 2023
    Assignee: Petra Pharma Corporation
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
  • FLUOROALKYL-OXADIAZOLES AND USES THEREOF
    Publication number: 20230143804
    Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.
    Type: Application
    Filed: December 23, 2022
    Publication date: May 11, 2023
    Inventors: Snahel PATEL, Mohammad A. MANDEGAR, David SPERANDIO, Julio MEDINA, Ulhas BHATT, Alok NERUKAR, Tien WIDJAJA
  • Opioid receptor modulators
    Patent number: 11634396
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: April 25, 2023
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
    Publication number: 20230123856
    Abstract: Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of heart disease.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 20, 2023
    Applicant: Tenaya Therapeutics, Inc.
    Inventors: Mohammad A. MANDEGAR, Snahel PATEL, Ulhas BHATT, Pingyu DING, Martin HOLAN, John LEE, Yihong LI, Julio MEDINA, Alok NERURKAR, Frederick SEIDL, David SPERANDIO, Tien WIDJAJA, Xiaodong WANG
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230096175
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Johnathan Alexander MCLEAN, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA
  • Fluoroalkyl-oxadiazoles and uses thereof
    Patent number: 11578066
    Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: February 14, 2023
    Assignee: Tenaya Therapeutics, Inc.
    Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230017140
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. Boyles, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230014445
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA, Nathan Edward WRIGHT
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20220372023
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 24, 2022
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • OPIOID RECEPTOR MODULATORS
    Publication number: 20220356157
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: April 5, 2022
    Publication date: November 10, 2022
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI